Business
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 8, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ...
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~","length":109,"tagName":"p"},{"type":"text","content":"SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the European Patent Office for the issuance of a patent* for PF8026, a groundbreaking Attention-Deficit/Hyperactivity Disorder (ADHD) therapy. PF8026 is a novel immediate-release amphetamine prodrug protected by the Company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.","length":691,"tagName":"p"},{"type":"text","content":"This newly allowed patent, covering both composition of matter and method of use claims, adds to the Ensysce patent portfolio and secures its subject-matter authority in developing safer treatments for ADHD, a condition affecting millions of children and adults worldwide.","length":272,"tagName":"p"},{"type":"text","content":"Amphetamine stimulants remain the standard of care for ADHD but carry well-documented risks of abuse, dependence, and overdose. Approximately 3.9 million people aged 12 or older misused prescription stimulants in 2023.** PF8026 represents another drug candidate in a new class of ADHD medications that directly address these risks. Unlike traditional formulations, Ensysce's prodrug design prevents common abuse routes such as nasal inhalation and incorporates MPAR® overdose protection that has been validated in clinical studies. With PF8026 (immediate release) and PF8001 (extended release) in its ADHD pipeline of TAAP products, Ensysce is expanding its product portfolio to include the first abuse-deterrent, overdose-protected stimulant therapies.","length":757,"tagName":"p"},{"type":"text","content":""Applying MPAR® technology to ADHD medications has the potential to save lives by reducing overdose," said Dr. Richard Dart, Director of the Rocky Mountain Poison and Drug Center, a leading expert in emergency medicine and toxicology.","length":244,"tagName":"p"},{"type":"text","content":""Our mission...